(Reuters) -The U.S. Food and Drug Administration (FDA) on Friday approved a pair of gene therapies for sickle cell disease, including the first treatment based on the breakthrough CRISPR gene editing technology. The agency approved Lyfgenia from bluebird bio, and a separate treatment called Casgevy by partners Vertex Pharmaceuticals and CRISPR Therapeutics. The Vertex/CRISPR gene therapy uses the breakthrough gene editing technology that won its inventors the Nobel Prize in 2020.
The US Food and Drug Administration (FDA) has approved two gene therapies for sickle cell disease, including the first treatment in the US based on CRISPR gene editing technology. Casgevy, developed by Vertex Pharmaceuticals and CRISPR Therapeutics, and bluebird bio s Lyfgenia were approved for people aged 12 years and older.
The Food and Drug Administration (FDA) on Friday approved a new therapy for treating sickle cell disease, marking the first instance of CRISPR gene editing receiving approval from federal regulators. The FDA approved on Friday two new treatments for sickle cell disease (SCD): Casgevy and Lyfgenia. Casgevy, also known as exa-cel, is developed through a…
The Food and Drug Administration Friday approved a new sickle cell disease treatment using the CRISPR genome editing technology. It's the first approved human gene editing therapy.